MEK pathway is activated by inducing mutations of major oncogenic proteins or growth factors, thus leading to enhanced cellular growth, invasion, development, and resistance to therapy during carcinogenesis and maintenance of colorectal cancer [26]. This evidence concerns the gene MAP2K7 and colorectal cancer.